Sequence: CGRKKRRQRRR
| Experiment Id | EXP002409 |
|---|---|
| Paper | Nanogels Enable Efficient miRNA Delivery and Target Gene Downregulation in Transfection-Resistant Mu |
| Peptide | HIV-1 TAT |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | ~9.5 TAT molecules per nanogel particle |
| Rna Concentration | 0.8–1.6 nmol miR-34a per formulation |
| Mixing Ratio | 5:1 N/P, 1.6 nmol miR-34a |
| Formulation Format | redox-sensitive poly(glycidol) nanogel |
| Formulation Components | poly(glycidol) nanogel + covalently bound TAT peptide + complexed miR-34a |
| Size Nm | 207.00 |
| Zeta Mv | 3.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | OPM-2 multiple myeloma cells (also screened: MM.1S, AMO-1) |
| Animal Model | |
| Administration Route | cell culture incubation with nanogels |
| Output Type | target gene downregulation |
| Output Value | Significant downregulation of Notch1, Hey1, Hes1, Hes6 |
| Output Units | |
| Output Notes | NG TAT/miR-34a-3 shows efficient uptake (SIM + flow cytometry) and functional miR-34a-mediated gene regulation. |
| Toxicity Notes | Low cytotoxicity; viability reduction only after functional miR-34a delivery |
| Curation Notes |